Fragile X syndrome: From protein function to therapy

American Journal of Medical Genetics, Part A

Volumn 161, Issue 11, 2013, Pages 2809-2821

  Bagni, Claudia ^a,b   Oostra, Ben A ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

FMR1; Fmr1 KO mouse; FMRP; Fragile X syndrome; Intellectual disability; Protein function; Review; Treatment

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID B RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALFAXALONE; ARBACLOFEN; FENOBAM; FRAGILE X MENTAL RETARDATION PROTEIN; GABOXADOL; GANAXOLONE; GELATINASE B; LEVACECARNINE; MAVOGLURANT; MESSENGER RNA; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR ANTAGONIST; MEVINOLIN; MINOCYCLINE; PLACEBO; PROTEIN TYROSINE PHOSPHATASE; R BACLOFEN; RO 4917523; STRIATAL ENRICHED PROTEIN TYROSINE PHOSPHATASE 9; STX 107; TAURINE; UNCLASSIFIED DRUG; VALPROIC ACID;

AMINO ACID SEQUENCE; ANXIETY; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; AUDIOGENIC SEIZURE; CELL MIGRATION; COMPULSION; DEPTH PERCEPTION; DROSOPHILA MELANOGASTER; DRUG TARGETING; FMR1 GENE; FRAGILE X SYNDROME; GENE; GENE SILENCING; HUMAN; HYPERACTIVITY; HYPERCHOLESTEROLEMIA; LOCOMOTION; MEMORY DISORDER; MUS MUSCULUS; NERVE CELL PLASTICITY; NEUROLOGIC DISEASE; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN SYNTHESIS REGULATION; RNA STABILITY; RNA TRANSPORT; SEIZURE; SIMPLE SEQUENCE REPEAT; SINGLE DRUG DOSE; SPATIAL LEARNING; STARTLE REFLEX; TESTIS WEIGHT; UBIQUITINATION; ZEBRA FISH;

ANIMALIA;

FMR1; FMR1 KO MOUSE; FMRP; FRAGILE X SYNDROME; INTELLECTUAL DISABILITY; PROTEIN FUNCTION; REVIEW; TREATMENT;

ANIMALS; DISEASE MODELS, ANIMAL; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; GABA AGONISTS; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, METABOTROPIC GLUTAMATE; SIGNAL TRANSDUCTION;

EID: 84886235508     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.36241     Document Type: Article

References (180)

1. Anderson P, Kedersha N. 2006. RNA granules. J Cell Biol 172:803-808.
2. Antar LN, Afroz R, Dictenberg JB, Carroll RC, Bassell GJ. 2004. Metabotropic glutamate receptor activation regulates fragile X mental retardation protein and FMR1 mRNA localization differentially in dendrites and at synapses. J Neurosci 24:2648-2655.
3. Antar LN, Dictenberg JB, Plociniak M, Afroz R, Bassell GJ. 2005. Localization of FMRP-associated mRNA granules and requirement of microtubules for activity-dependent trafficking in hippocampal neurons. Genes Brain Behav 4:350-359.
4. Antar LN, Li C, Zhang H, Carroll RC, Bassell GJ. 2006. Local functions for FMRP in axon growth cone motility and activity-dependent regulation of filopodia and spine synapses. Mol Cell Neurosci 32:37-48.
5. Ascano M, Mukherjee N, Bandaru P, Miller JB, Nusbaum JD, Corcoran DL, Langlois C, Munschauer M, Dewell S, Hafner M, Williams Z, Ohler U, Tuschl T. 2012. FMRP targets distinct mRNA sequence elements to regulate protein expression. Nature 492:382-386.
6. Ashley C Jr, Wilkinson KD, Reines D, Warren ST. 1993. FMR1 protein: Conserved RNP family domains and selective RNA binding. Science 262:563-568.
7. Auerbach BD, Osterweil EK, Bear MF. 2011. Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480:63-68.
8. Bagni C, Klann E. 2012. Molecular functions of the mammalian fragile X mental retardation protein: Insights into mental retardation and synaptic plasticity. In: Powell CM, Monteggia LM, editors. The autisms. pp 126-139.
9. Bagni C, Tassone F, Neri G, Hagerman R. 2012. Fragile X syndrome: Causes, diagnosis, mechanisms, and therapeutics. J Clin Invest 122:4314-4322.
10. Bakker CE, Oostra BA. 2003. Understanding fragile X syndrome: Insights from animal models. Cytogenet Genome Res 100:111-123.
11. Bakker CE, Verheij C, Willemsen R, Vanderhelm R, Oerlemans F, Vermey M, Bygrave A, Hoogeveen AT, Oostra BA, Reyniers E, Deboulle K, Dhooge R, Cras P, Van Velzen D, Nagels G, Martin JJ, Dedeyn PP, Darby JK, Willems PJ. 1994. Fmr1 knockout mice: A model to study fragile X mental retardation. Cell 78:23-33.
12. Bardoni B, Castets M, Huot ME, Schenck A, Adinolfi S, Corbin F, Pastore A, Khandjian EW, Mandel JL. 2003. 82-FIP, a novel FMRP (fragile X mental retardation protein) interacting protein, shows a cell cycle-dependent intracellular localization. Hum Mol Genet 12:1689-1698.
13. Bear MF, Huber KM, Warren ST. 2004. The mGluR theory of fragile X mental retardation. Trends Neurosci 27:370-377.
14. Berry-Kravis EM, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, Hutchison J, Snape M, Tranfaglia M, Nguyen DV, Hagerman R. 2009. A pilot open-label single-dose trial of fenobam in adults with fragile X syndrome. J Med Genet 46:266-271.
15. Berry-Kravis EM, Hessl D, Rathmell B, Zarevics P, Cherubini M, Walton-Bowen K, Mu Y, Nguyen DV, Gonzalez-Heydrich J, Wang PP, Carpenter RL, Bear MF, Hagerman RJ. 2012. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: A randomized, controlled, phase 2 trial. Sci Transl Med 4:152ra127.
16. Bilousova T, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM. 2008. Minocycline promotes dendritic spine maturation and improves behavioral performance in the fragile X mouse model. J Med Genet 46:94-102.
17. Brackett DM, Qing F, Amieux PS, Sellers DL, Horner PJ, Morris DR. 2013. FMR1 transcript isoforms: Association with polyribosomes; regional and developmental expression in mouse brain. PLoS ONE 8:e58296.
18. Bramham CR, Wells DG. 2007. Dendritic mRNA: Transport, translation and function. Nat Rev Neurosci 8:776-789.
19. Braun K, Segal M. 2000. FMRP involvement in formation of synapses among cultured hippocampal neurons. Cereb Cortex 10:1045-1052.
20. Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, Darnell RB, Warren ST. 2001. Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 107:477-487.
21. Bushey D, Tononi G, Cirelli C. 2009. The Drosophila fragile X mental retardation gene regulates sleep need. J Neurosci 29:1948-1961.
22. Ceman S, O'Donnell WT, Reed M, Patton S, Pohl J, Warren ST. 2003. Phosphorylation influences the translation state of FMRP-associated polyribosomes. Hum Mol Genet 12:3295-3305.
23. Chang S, Bray SM, Li Z, Zarnescu DC, He C, Jin P, Warren ST. 2008. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 4:256-263.
24. Cheever A, Ceman S. 2009. Phosphorylation of FMRP inhibits association with Dicer. RNA 15:362-366.
25. Chen L, Yun SW, Seto J, Liu W, Toth M. 2003. The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing u rich target sequences. Neuroscience 120:1005-1017.
26. Chuang SC, Zhao W, Bauchwitz R, Yan Q, Bianchi R, Wong RK. 2005. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J Neurosci 25:8048-8055.
27. Coffee B, Ikeda M, Budimirovic DB, Hjelm LN, Kaufmann WE, Warren ST. 2008. Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: A case report and review of the literature. Am J Med Genet Part A 146A:1358-1367.
28. Coffee RL Jr, Tessier CR, Woodruff EA III, Broadie K. 2010. Fragile X mental retardation protein has a unique, evolutionarily conserved neuronal function not shared with FXR1P or FXR2P. Dis Model Mech 3:471-485.
29. Collins SC, Coffee B, Benke PJ, Berry-Kravis E, Gilbert F, Oostra B, Halley D, Zwick ME, Cutler DJ, Warren ST. 2010. Array-based FMR1 sequencing and deletion analysis in patients with a fragile X syndrome-like phenotype. PLoS ONE 5:e9476.
30. Cruz-Martin A, Crespo M, Portera-Cailliau C. 2010. Delayed stabilization of dendritic spines in fragile X mice. J Neurosci 30:7793-7803.
31. Darnell JC, Klann E. 2013. The translation of translational control by FMRP: Therapeutic targets for FXS. Nat Neurosci, in press.
32. Darnell JC, Jensen KB, Jin P, Brown V, Warren ST, Darnell RB. 2001. Fragile X mental retardation protein targets G quartet mRNAs important for neuronal function. Cell 107:489-499.
33. Darnell JC, Van Driesche SJ, Zhang C, Hung KY, Mele A, Fraser CE, Stone EF, Chen C, Fak JJ, Chi SW, Licatalosi DD, Richter JD, Darnell RB. 2011. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146:247-261.
34. Davidovic L, Bechara E, Gravel M, Jaglin XH, Tremblay S, Sik A, Bardoni B, Khandjian EW. 2006. The nuclear microspherule protein 58 is a novel RNA-binding protein that interacts with fragile X mental retardation protein in polyribosomal mRNPs from neurons. Hum Mol Genet 15:1525-1538.
35. Davidovic L, Jaglin XH, Lepagnol-Bestel AM, Tremblay S, Simonneau M, Bardoni B, Khandjian EW. 2007. The fragile X mental retardation protein is a molecular adaptor between the neurospecific KIF3C kinesin and dendritic RNA granules. Hum Mol Genet 16:3047-3058.
36. De Boulle K, Verkerk AJ, Reyniers E, Vits L, Hendrickx J, Van Roy B, Van den Bos F, de Graaff E, Oostra BA, Willems PJ. 1993. A point mutation in the FMR-1 gene associated with fragile X mental retardation. Nat Genet 3:31-35.
37. De Rubeis S, Bagni C. 2010. Fragile X mental retardation protein control of neuronal mRNA metabolism: Insights into mRNA stability. Mol Cell Neurosci 43:43-50.
38. De Rubeis S, Fernandez E, Buzzi A, Di Marino D, Bagni C. 2012. Molecular and cellular aspects of mental retardation in the fragile X syndrome: From gene mutation/s to spine dysmorphogenesis. Adv Exp Med Biol 970:517-551.
39. De Vrij FMS, Levenga J, Van der Linde HC, Koekkoek SK, De Zeeuw CI, Nelson DL, Oostra BA, Willemsen R. 2008. Rescue of behavioral phenotype and neuronal protrusion morphology in FMR1 KO mice. Neurobiol Dis 31:127-132.
40. den Broeder MJ, van der Linde H, Brouwer JR, Oostra BA, Willemsen R, Ketting RF. 2009. Generation and characterization of FMR1 knockout zebrafish. PLoS ONE 4:e7910.
41. D'Hulst C, Kooy RF. 2007. The GABA(A) receptor: A novel target for treatment of fragile X? Trends Neurosci 30:425-431.
42. D'Hulst C, De Geest N, Reeve SP, Van Dam D, De Deyn PP, Hassan BA, Kooy RF. 2006. Decreased expression of the GABA(A) receptor in fragile X syndrome. Brain Res 1121:238-245.
43. Di Marino D, Achsel T, Lacoux C, Falconi M, Bagni C. 2013. Molecular dynamics simulations show how the FMRP Ile304Asn mutation destabilizes the KH2 domain structure and affects its function. J Biomol Struct Dyn, in press.
44. Dictenberg JB, Swanger SA, Antar LN, Singer RH, Bassell GJ. 2008. A direct role for FMRP in activity-dependent dendritic mRNA transport links filopodial-spine morphogenesis to fragile X syndrome. Dev Cell 14:926-939.
45. Dolen G, Osterweil E, Rao BS, Smith GB, Auerbach BD, Chattarji S, Bear MF. 2007. Correction of fragile X syndrome in mice. Neuron 56:955-962.
46. Dolen G, Carpenter RL, Ocain TD, Bear MF. 2010. Mechanism-based approaches to treating fragile X. Pharmacol Ther 127:78-93.
47. Eberhart DE, Malter HE, Feng Y, Warren ST. 1996. The fragile X mental retardation protein is a ribosonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet 5:1083-1091.
48. Edbauer D, Neilson JR, Foster KA, Wang CF, Seeburg DP, Batterton MN, Tada T, Dolan BM, Sharp PA, Sheng M. 2010. Regulation of synaptic structure and function by FMRP-associated microRNAs miR-125b and miR-132. Neuron 65:373-384.
49. El Idrissi A, Ding XH, Scalia J, Trenkner E, Brown WT, Dobkin C. 2005. Decreased GABA(A) receptor expression in the seizure-prone fragile X mouse. Neurosci Lett 377:141-146.
50. El Idrissi A, Neuwirth LS, L'Amoreaux W. 2010. Taurine regulation of short term synaptic plasticity in fragile X mice. J Biomed Sci 17:S15.
51. Engels B, Van 't Padje S, Blonden L, Severijnen LA, Oostra BA, Willemsen R. 2004. Characterization of Fxr1 in Danio rerio; a simple vertebrate model to study costamere development. J Exp Biol 207:3329-3338.
52. Fernandez-Carvajal I, Lopez Posadas B, Pan R, Raske C, Hagerman PJ, Tassone F. 2009. Expansion of an FMR1 grey-zone allele to a full mutation in two generations. J Mol Diagn 11:306-310.
53. Ferrari F, Mercaldo V, Piccoli G, Sala C, Cannata S, Achsel T, Bagni C. 2007. The fragile X mental retardation protein-RNP granules show an mGluR-dependent localization in the post-synaptic spines. Mol Cell Neurosci 34:343-354.
54. Flavell SW, Greenberg ME. 2008. Signaling mechanisms linking neuronal activity to gene expression and plasticity of the nervous system. Annu Rev Neurosci 31:563-590.
55. Fu YH, Kuhl DP, Pizzuti A, Pieretti M, Sutcliffe JS, Richards S, Verkerk AJ, Holden JJ, Fenwick R Jr, Warren ST, Oostra BA, Nelson DL, Caskey CT. 1991. Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox. Cell 67:1047-1058.
56. Galvez R, Greenough WT. 2005. Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. Am J Med Genet Part A 135A:155-160.
57. Gantois I, Vandesompele J, Speleman F, Reyniers E, D'Hooge R, Severijnen LA, Willemsen R, Tassone F, Kooy RF. 2006. Expression profiling suggests underexpression of the GABA(A) receptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis 21:346-357.
58. Gantois I, Pop AS, de Esch CE, Buijsen RA, Pooters T, Gomez-Mancilla B, Gasparini F, Oostra BA, D'Hooge R, Willemsen R. 2013. Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice. Behav Brain Res 239:72-79.
59. Gessert S, Bugner V, Tecza A, Pinker M, Kuhl M. 2010. FMR1/FXR1 and the miRNA pathway are required for eye and neural crest development. Dev Biol 341:222-235.
60. Gladding CM, Fitzjohn SM, Molnar E. 2009. Metabotropic glutamate receptor-mediated long-term depression: Molecular mechanisms. Pharmacol Rev 61:395-412.
61. Goebel-Goody SM, Baum M, Paspalas CD, Fernandez SM, Carty NC, Kurup P, Lombroso PJ. 2012. Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol Rev 64:65-87.
62. Greenough WT, Klintsova AY, Irwin SA, Galvez R, Bates KE, Weiler IJ. 2001. Synaptic regulation of protein synthesis and the fragile X protein. Proc Natl Acad Sci USA 98:7101-7106.
63. Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, Ye K, Warren ST, Bassell GJ. 2010. Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci 30:10624-10638.
64. Gross C, Berry-Kravis EM, Bassell GJ. 2012. Therapeutic strategies in fragile X syndrome: Dysregulated mGluR signaling and beyond. Neuropsychopharmacology 37:178-195.
65. Grossman AW, Elisseou NM, McKinney BC, Greenough WT. 2006. Hippocampal pyramidal cells in adult Fmr1 knockout mice exhibit an immature-appearing profile of dendritic spines. Brain Res 1084:158-164.
66. Guo W, Allan AM, Zong R, Zhang L, Johnson EB, Schaller EG, Murthy AC, Goggin SL, Eisch AJ, Oostra BA, Nelson DL, Jin P, Zhao X. 2011. Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med 19:559-565.
67. Hagerman RJ. 2002. The physical and behavioural phenotype. In: Hagerman RJ, Hagerman P, editors. Fragile-X syndrome: Diagnosis, treatment and research. Baltimore, Md, USA: The Johns Hopkins University Press. pp 3-109.
68. Hagerman R, Lauterborn J, Au J, Berry-Kravis E. 2012. Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ 54:297-335.
69. Henderson C, Wijetunge L, Kinoshita MN, Shumway M, Hammond RS, Postma FR, Brynczka C, Rush R, Thomas A, Paylor R, Warren ST, Vanderklish PW, Kind PC, Carpenter RL, Bear MF, Healy AM. 2012. Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABA(B) receptors with arbaclofen. Sci Transl Med 4:152ra128.
70. Heulens I, D'Hulst C, Van Dam D, De Deyn PP, Kooy RF. 2012. Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model. Behav Brain Res 229:244-249.
71. Holt CE, Bullock SL. 2009. Subcellular mRNA localization in animal cells and why it matters. Science 326:1212-1216.
72. Hou L, Antion MD, Hu D, Spencer CM, Paylor R, Klann E. 2006. Dynamic translational and proteasomal regulation of Fragile X mental retardation protein controls mGluR-dependent long-term depression. Neuron 51:441-454.
73. Huber KM, Gallagher SM, Warren ST, Bear MF. 2002. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 99:7746-7750.
74. Irwin SA, Idupulapati M, Gilbert ME, Harris JB, Chakravarti AB, Rogers EJ, Crisostomo RA, Larsen BP, Mehta A, Alcantara CJ, Patel B, Swain RA, Weiler IJ, Oostra BA, Greenough WT. 2002. Dendritic spine and dendritic field characteristics of layer V pyramidal neurons in the visual cortex of fragile-X knockout mice. Am J Med Genet 111:140-146.
75. Ishizuka A, Siomi MC, Siomi H. 2002. A Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins. Genes Dev 16:2497-2508.
76. Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe G, Johns D, Gomez-Mancilla B. 2011. Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. Sci Transl Med 3:64ra1.
77. Johnson EM, Kinoshita Y, Weinreb DB, Wortman MJ, Simon R, Khalili K, Winckler B, Gordon J. 2006. Role of Pur alpha in targeting mRNA to sites of translation in hippocampal neuronal dendrites. J Neurosci Res 83:929-943.
78. Jung H, Yoon BC, Holt CE. 2012. Axonal mRNA localization and local protein synthesis in nervous system assembly, maintenance and repair. Nat Rev Neurosci 13:308-324.
79. Kanai Y, Dohmae N, Hirokawa N. 2004. Kinesin transports RNA: Isolation and characterization of an RNA-transporting granule. Neuron 43:513-525.
80. Kanellopoulos AK, Semelidou O, Kotini AG, Anezaki M, Skoulakis EM. 2012. Learning and memory deficits consequent to reduction of the fragile X mental retardation protein result from metabotropic glutamate receptor-mediated inhibition of cAMP signaling in Drosophila. J Neurosci 32:13111-13124.
81. Kao DI, Aldridge GM, Weiler IJ, Greenough WT. 2010. Altered mRNA transport, docking, and protein translation in neurons lacking fragile X mental retardation protein. Proc Natl Acad Sci USA 107:15601-15606.
82. Kaufmann WE, Cohen S, Sun HT, Ho G. 2002. Molecular phenotype of fragile X syndrome: FMRP, FXRPs, and protein targets. Microsc Res Tech 57:135-144.
83. Khandjian EW, Huot ME, Tremblay S, Davidovic L, Mazroui R, Bardoni B. 2004. Biochemical evidence for the association of fragile X mental retardation protein with brain polyribosomal ribonucleoparticles. Proc Natl Acad Sci USA 101:13357-13362.
84. Kooy RF. 2003. Of mice and the fragile X syndrome. Trends Genet 19:148-154.
85. Krueger DD, Osterweil EK, Chen SP, Tye LD, Bear MF. 2011. Cognitive dysfunction and prefrontal synaptic abnormalities in a mouse model of fragile X syndrome. Proc Natl Acad Sci USA 108:2587-2592.
86. Laggerbauer B, Ostareck D, Keidel EM, Ostareck-Lederer A, Fischer U. 2001. Evidence that fragile X mental retardation protein is a negative regulator of translation. Hum Mol Genet 10:329-338.
87. Levenga J, de Vrij FM, Oostra BA, Willemsen R. 2010. Potential therapeutic interventions for fragile X syndrome. Trends Mol Med 16:516-527.
88. Levenga J, de Vrij FM, Buijsen RA, Li T, Nieuwenhuizen IM, Pop A, Oostra BA, Willemsen R. 2011a. Subregion-specific dendritic spine abnormalities in the hippocampus of Fmr1 KO mice. Neurobiol Learn Mem 95:467-472.
89. Levenga J, Hayashi S, de Vrij FM, Koekkoek SK, van der Linde HC, Nieuwenhuizen I, Song C, Buijsen RA, Pop AS, GomezMancilla B, Nelson DL, Willemsen R, Gasparini F, Oostra BA. 2011b. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 42:311-317.
90. Li Z, Zhang Y, Ku L, Wilkinson KD, Warren ST, Feng Y. 2001. The fragile X mental retardation protein inhibits translation via interacting with mRNA. Nucleic Acids Res 29:2276-2283.
91. Li W, Cui Y, Kushner SA, Brown RA, Jentsch JD, Frankland PW, Cannon TD, Silva AJ. 2005. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol 15:1961-1967.
92. Lindemann L, Jaeschke G, Michalon A, Vieira E, Honer M, Spooren W, Porter R, Hartung T, Kolczewski S, Buttelmann B, Flament C, Diener C, Fischer C, Gatti S, Prinssen EP, Parrott N, Hoffmann G, Wettstein JG. 2011. CTEP-A novel, potent, long-acting and orally bioavailable mGlu5 inhibitor. J Pharmacol Exp Ther 339:474-486.
93. Linder B, Plottner O, Kroiss M, Hartmann E, Laggerbauer B, Meister G, Keidel E, Fischer U. 2008. Tdrd3 is a novel stress granule-associated protein interacting with the fragile-X syndrome protein FMRP. Hum Mol Genet 17:3236-3246.
94. Liu W, Jiang F, Bi X, Zhang YQ. 2012. Drosophila FMRP participates in the DNA damage response by regulating G2/M cell cycle checkpoint and apoptosis. Hum Mol Genet 21:4655-4668.
95. Lu R, Wang H, Liang Z, Ku L, O'Donnell WT, Li W, Warren ST, Feng Y. 2004. The fragile X protein controls microtubule-associated protein 1B translation and microtubule stability in brain neuron development. Proc Natl Acad Sci USA 101:15201-15206.
96. Massey PV, Bashir ZI. 2007. Long-term depression: Multiple forms and implications for brain function. Trends Neurosci 30:176-184.
97. McBride SM, Choi CH, Wang Y, Liebelt D, Braunstein E, Ferreiro D, Sehgal A, Siwicki KK, Dockendorff TC, Nguyen HT, McDonald TV, Jongens TA. 2005. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 45:753-764.
98. McKinney BC, Grossman AW, Elisseou NM, Greenough WT. 2005. Dendritic spine abnormalities in the occipital cortex of C57BL/6 Fmr1 knockout mice. Am J Med Genet Part B 136B:98-102.
99. McNaughton CH, Moon J, Strawderman MS, Maclean KN, Evans J, Strupp BJ. 2008. Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome. Behav Neurosci 122:293-300.
100. Menon RP, Gibson TJ, Pastore A. 2004. The C terminus of fragile X mental retardation protein interacts with the multi-domain Ran-binding protein in the microtubule-organising centre. J Mol Biol 343:43-53.
101. Michalon A, Sidorov M, Ballard TM, Ozmen L, Spooren W, Wettstein JG, Jaeschke G, Bear MF, Lindemann L. 2012. Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74:49-56.
102. Mientjes EJ, Nieuwenhuizen I, Kirkpatrick L, Zu T, Hoogeveen-Westerveld M, Severijnen L, Rife M, Willemsen R, Nelson DL, Oostra BA. 2006. The generation of a conditional Fmr1 knock out mouse model to study Fmrp function in vivo. Neurobiol Dis 21:549-555.
103. Mineur YS, Sluyter F, de WS, Oostra BA, Crusio WE. 2002. Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse. Hippocampus 12:39-46.
104. Miyashiro KY, Beckel-Mitchener A, Purk TP, Becker KG, Barret T, Liu L, Carbonetto S, Weiler IJ, Greenough WT, Eberwine J. 2003. RNA cargoes associating with fmrp reveal deficits in cellular functioning in Fmr1 null mice. Neuron 37:417-431.
105. Monzo K, Papoulas O, Cantin GT, Wang Y, Yates JR III, Sisson JC. 2006. Fragile X mental retardation protein controls trailer hitch expression and cleavage furrow formation in Drosophila embryos. Proc Natl Acad Sci USA 103:18160-18165.
106. Muddashetty R, Bassell GJ. 2009. A boost in microRNAs shapes up the neuron. EMBO J 28:617-618.
107. Muddashetty RS, Kelic S, Gross C, Xu M, Bassell GJ. 2007. Dysregulated metabotropic glutamate receptor-dependent translation of AMPA receptor and postsynaptic density-95 mRNAs at synapses in a mouse model of fragile X syndrome. J Neurosci 27:5338-5348.
108. Muddashetty RS, Nalavadi VC, Gross C, Yao X, Xing L, Laur O, Warren ST, Bassell GJ. 2011. Reversible inhibition of PSD-95 mRNA translation by miR-125a, FMRP phosphorylation, and mGluR signaling. Mol Cell 42:673-688.
109. Musco G, Stier G, Joseph C, Castilioni Morelli MA, Nilges M, J GT, Pastore A. 1996. Three-dimensional structure and stability of the KH domain: Molecular insights into the fragile X syndrome. Cell 85:237-245.
110. Musumeci SA, Bosco P, Calabrese G, Bakker C, De Sarro GB, Elia M, Ferri R, Oostra BA. 2000. Audiogenic seizures susceptibility in transgenic mice with fragile X syndrome. Epilepsia 41:19-23.
111. Musumeci SA, Calabrese G, Bonaccorso CM, D'Antoni S, Brouwer JR, Bakker CE, Elia M, Ferri R, Nelson DL, Oostra BA, Catania MV. 2007. Audiogenic seizure susceptibility is reduced in fragile X knockout mice after introduction of FMR1 transgenes. Exp Neurol 203:233-240.
112. Napoli I, Mercaldo V, Boyl PP, Eleuteri B, Zalfa F, De Rubeis S, Di Marino D, Mohr E, Massimi M, Falconi M, Witke W, Costa-Mattioli M, Sonenberg N, Achsel T, Bagni C. 2008. The fragile X syndrome protein represses activity-dependent translation through CYFIP1, a new 4E-BP. Cell 134:1042-1054.
113. Narayanan U, Nalavadi V, Nakamoto M, Pallas DC, Ceman S, Bassell GJ, Warren ST. 2007. FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A. J Neurosci 27:14349-14357.
114. Nelson DL, Orr HT, Warren ST. 2013. The unstable repeats-Three evolving faces of neurological disease. Neuron 77:825-843.
115. Nimchinsky EA, Oberlander AM, Svoboda K. 2001. Abnormal development of dendritic spines in fmr1 knock-out mice. J Neurosci 21:5139-5146.
116. Nosyreva ED, Huber KM. 2006. Metabotropic receptor-dependent long-term depression persists in the absence of protein synthesis in the mouse model of fragile X syndrome. J Neurophysiol 95:3291-3295.
117. Oberlé I, Rousseau F, Heitz D, Kretz C, Devys D, Hanauer A, Boue J, Bertheas MF, Mandel JL. 1991. Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science 252:1097-1102.
118. O'Donnell WT, Warren ST. 2002. A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci 25:315-338.
119. Olmos-Serrano JL, Corbin JG. 2011. Amygdala regulation of fear and emotionality in fragile X syndrome. Dev Neurosci 33:356-378.
120. Osterweil EK, Krueger DD, Reinhold K, Bear MF. 2010. Hypersensitivity to mGluR5 and ERK1/2 leads to excessive protein synthesis in the hippocampus of a mouse model of fragile X syndrome. J Neurosci 30:15616-15627.
121. Osterweil EK, Chuang SC, Chubykin AA, Sidorov M, Bianchi R, Wong RK, Bear MF. 2013. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77:243-250.
122. Pacey LK, Heximer SP, Hampson DR. 2009. Increased GABAB receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol 76:18-24.
123. Pacey LK, Doss L, Cifelli C, der Kooy DV, Heximer SP, Hampson DR. 2011. Genetic deletion of regulator of G-protein signaling 4 (RGS4) rescues a subset of fragile X related phenotypes in the FMR1 knockout mouse. Mol Cell Neurosci 46:563-572.
124. Papoulas O, Monzo KF, Cantin GT, Ruse C, Yates JR III, Ryu YH, Sisson JC. 2010. dFMRP and Caprin, translational regulators of synaptic plasticity, control the cell cycle at the Drosophila mid-blastula transition. Development 137:4201-4209.
125. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW. 2010. Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 10:91.
126. Piazzon N, Rage F, Schlotter F, Moine H, Branlant C, Massenet S. 2008. In vitro and in cellulo evidences for association of the survival of motor neuron complex with the fragile X mental retardation protein. J Biol Chem 283:5598-5610.
127. Pietropaolo S, Guilleminot A, Martin B, D'Amato FR, Crusio WE. 2011. Genetic-background modulation of core and variable autistic-like symptoms in FMR1 knock-out mice. PLoS ONE 6:e17073.
128. Pop AS, Gomez-Mancilla B, Neri G, Willemsen R, Gasparini F. 2013a. Fragile X syndrome: A preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development. Psychopharmacology, in press.
129. Pop AS, Levenga J, de Esch CE, Buijsen RA, Nieuwenhuizen IM, Li T, Isaacs A, Gasparini F, Oostra BA, Willemsen R. 2013b. Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056/Mavoglurant. Psychopharmacology, in press.
130. Portera-Cailliau C. 2011. Which comes first in fragile X syndrome, dendritic spine dysgenesis or defects in circuit plasticity? Neuroscientist 18:28-44.
131. Ramos A, Hollingworth D, Adinolfi S, Castets M, Kelly G, Frenkiel TA, Bardoni B, Pastore A. 2006. The structure of the N-terminal domain of the fragile X mental retardation protein: A platform for protein-protein interaction. Structure 14:21-31.
132. Restivo L, Ferrari F, Passino E, Sgobio C, Bock J, Oostra BA, Bagni C, Ammassari-Teule M. 2005. Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc Natl Acad Sci USA 102:11557-11562.
133. Ronesi JA, Huber KM. 2008. Metabotropic glutamate receptors and fragile X mental retardation protein: Partners in translational regulation at the synapse. Sci Signal 1:pe6.
134. Rotschafer S, Razak K. 2013. Altered auditory processing in a mouse model of fragile X syndrome. Brain Res 1506:12-24.
135. Rotschafer SE, Trujillo MS, Dansie LE, Ethell IM, Razak KA. 2011. Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of fragile X syndrome. Brain Res 1439:7-14.
136. Scantlebury N, Zhao XL, Rodriguez Moncalvo VG, Camiletti A, Zahanova S, Dineen A, Xin JH, Campos AR. 2010. The Drosophila gene RanBPM functions in the mushroom body to regulate larval behavior. PLoS ONE 5:e10652.
137. Schenck A, Bardoni B, Moro A, Bagni C, Mandel JL. 2001. A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displaying selective interactions with FMRP-related proteins FXR1P and FXR2P. Proc Natl Acad Sci USA 98:8844-8849.
138. Schenck A, Bardoni B, Langmann C, Harden N, Mandel JL, Giangrande A. 2003. CYFIP/Sra-1 controls neuronal connectivity in drosophila and links the Rac1 GTPase pathway to the fragile X protein. Neuron 38:887-898.
139. Schutt J, Falley K, Richter D, Kreienkamp HJ, Kindler S. 2009. Fragile X mental retardation protein regulates the levels of scaffold proteins and glutamate receptors in postsynaptic densities. J Biol Chem 284:25479-25487.
140. Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, Zukin RS. 2010. Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 30:694-702.
141. Sherman SL, Jacobs PA, Morton NE, Froster-Iskenius U, Howard-Peebles PN, Nielsen KB, Partington MW, Sutherland GR, Turner G, Watson M. 1985. Further segregation analysis of the fragile X syndrome with special reference to transmitting males. Hum Genet 69:289-299.
142. Shi SH, Hayashi Y, Petralia RS, Zaman SH, Wenthold RJ, Svoboda K, Malinow R. 1999. Rapid spine delivery and redistribution of AMPA receptors after synaptic NMDA receptor activation. Science 284:1811-1816.
143. Siomi H, Siomi MC, Nussbaum RL, Dreyfuss G. 1993. The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein. Cell 74:291-298.
144. Siomi MC, Zhang Y, Siomi H, Dreyfuss G. 1996. Specific sequences in the fragile X syndrome protein FMR1 and the FXR proteins mediate their binding to 60S ribosomal subunits and the interactions among them. Moll Cell Biol 16:3825-3832.
145. Sittler A, Devys D, Weber C, Mandel J-L. 1996. Alternative splicing of exon 14 determines nuclear or cytoplasmic localisation of FMR1 protein isoforms. Hum Mol Genet 5:95-102.
146. Sjekloca L, Konarev PV, Eccleston J, Taylor IA, Svergun DI, Pastore A. 2009. A study of the ultrastructure of fragile-X-related proteins. Biochem J 419:347-357.
147. Spencer CM, Alekseyenko O, Serysheva E, Yuva-Paylor LA, Paylor R. 2005. Altered anxiety-related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome. Genes Brain Behav 4:420-430.
148. Spencer CM, Alekseyenko O, Hamilton SM, Thomas AM, Serysheva E, Yuva-Paylor LA, Paylor R. 2011. Modifying behavioral phenotypes in Fmr1KO mice: Genetic background differences reveal autistic-like responses. Autism Res 4:40-56.
149. Stefani G, Fraser CE, Darnell JC, Darnell RB. 2004. Fragile X mental retardation protein is associated with translating polyribosomes in neuronal cells. J Neurosci 24:9272-9276.
150. Steward O, Schuman EM. 2003. Compartmentalized synthesis and degradation of proteins in neurons. Neuron 40:347-359.
151. Sutcliffe JS, Nelson DL, Zhang F, Pieretti M, Caskey CT, Saxe D, Warren ST. 1992. DNA methylation represses FMR-1 transcription in fragile X syndrome. Hum Mol Genet 1:397-400.
152. Tamanini F, Van Unen L, Bakker C, Sacchi N, Galjaard H, Oostra BA, Hoogeveen AT. 1999. Oligomerization properties of fragile-X mental-retardation protein (FMRP) and the fragile-X-related proteins FXR1P and FXR2P. Biochem J 343:517-523.
153. Tian H, Cao YX, Zhang XS, Liao WP, Yi YH, Lian J, Liu L, Huang HL, Liu WJ, Yin MM, Liang M, Shan G, Sun F. 2013. The targeting and functions of miRNA-383 are mediated by FMRP during spermatogenesis. Cell Death Dis 4:e617.
154. Till SM, Wijetunge LS, Seidel VG, Harlow E, Wright AK, Bagni C, Contractor A, Gillingwater TH, Kind PC. 2012. Altered maturation of the primary somatosensory cortex in a mouse model of fragile X syndrome. Hum Mol Genet 21:2143-2156.
155. Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila M, Militerni R, Musumeci S, Ramos FJ, Frontera M, Sorge G, Marzullo E, Romeo G, Vallee L, Veneselli E, Cocchi E, Garbarino E, Moscato U, Chiurazzi P, D'Iddio S, Calvani M, Neri G. 2008. A double-blind, parallel, multicenter comparison of l-acetylcarnitine with placebo on the attention deficit hyperactivity disorder in fragile X syndrome boys. Am J Med Genet Part A 146A:803-812.
156. Torrioli M, Vernacotola S, Setini C, Bevilacqua F, Martinelli D, Snape M, Hutchison JA, Di Raimo FR, Tabolacci E, Neri G. 2010. Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys. Am J Med Genet Part A 152A:1420-1427.
157. Tsai NP, Wilkerson JR, Guo W, Maksimova MA, Demartino GN, Cowan CW, Huber KM. 2012. Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95. Cell 151:1581-1594.
158. Tucker B, Richards R, Lardelli M. 2004. Expression of three zebrafish orthologs of human FMR1-related genes and their phylogenetic relationships. Dev Genes Evol 214:567-574.
159. Tucker B, Richards RI, Lardelli M. 2006. Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome. Hum Mol Genet 15:3446-3458.
160. Utari A, Chonchaiya W, Rivera SM, Schneider A, Hagerman RJ, Faradz SM, Ethell IM, Nguyen DV. 2010. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil 115:433-443.
161. Valverde R, Pozdnyakova I, Kajander T, Venkatraman J, Regan L. 2007. Fragile X mental retardation syndrome: Structure of the KH1-KH2 domains of Fragile X mental retardation protein. Structure 15:1090-1098.
162. Valverde R, Edwards L, Regan L. 2008. Structure and function of KH domains. FEBS J 275:2712-2726.
163. van 't Padje S, Engels B, Blonden L, Severijnen LA, Verheijen F, Oostra BA, Willemsen R. 2005. Characterisation of Fmrp in zebrafish: Evolutionary dynamics of the fmr1 gene. Dev Genes Evol 215:198-206.
164. Verheij C, Bakker CE, de Graaff E, Keulemans J, Willemsen R, Verkerk AJ, Galjaard H, Reuser AJ, Hoogeveen AT, Oostra BA. 1993. Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature 363:722-724.
165. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, Reiner O, Richards S, Victoria MF, Zhang FP, Eussen BE, Van Ommen GJB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galjaard H, Caskey CT, Nelson DL, Oostra BA, Warren ST. 1991. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 65:905-914.
166. Verkerk AJ, De Graaff E, De Boulle K, Eichler EE, Konecki DS, Reyniers E, Manca A, Poustka A, Willems PJ, Nelson DL, Oostra BA. 1993. Alternative splicing in the fragile X gene FMR1. Hum Mol Genet 2:399-404.
167. Vigot R, Barbieri S, Brauner-Osborne H, Turecek R, Shigemoto R, Zhang YP, Lujan R, Jacobson LH, Biermann B, Fritschy JM, Vacher CM, Muller M, Sansig G, Guetg N, Cryan JF, Kaupmann K, Gassmann M, Oertner TG, Bettler B. 2006. Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron 50:589-601.
168. Wan L, Dockendorff TC, Jongens TA, Dreyfuss G. 2000. Characterization of dFMR1, a Drosophila melanogaster homolog of the Fragile X mental retardation protein. Mol Cell Biol 20:8536-8547.
169. Wijetunge LS, Chattarji S, Wyllie DJ, Kind PC. 2013. Fragile X syndrome: From targets to treatments. Neuropharmacology 68:83-96.
170. Willemsen R, Bontekoe C, Tamanini F, Galjaard H, Hoogeveen AT, Oostra BA. 1996. Association of FMRP with ribosomal precursor particles in the nucleolus. Biochem Biophys Res Comm 225:27-33.
171. Xie W, Dolzhanskaya N, LaFauci G, Dobkin C, Denman RB. 2009. Tissue and developmental regulation of fragile X mental retardation 1 exon 12 and 15 isoforms. Neurobiol Dis 35:52-62.
172. Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. 2005. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 49:1053-1066.
173. Zalfa F, Giorgi M, Primerano B, Moro A, Di Penta A, Reis S, Oostra B, Bagni C. 2003. The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses. Cell 112:317-327.
174. Zalfa F, Adinolfi S, Napoli I, Kuhn-Holsken E, Urlaub H, Achsel T, Pastore A, Bagni C. 2005. Fragile X mental retardation protein (FMRP) binds specifically to the brain cytoplasmic RNAs BC1/BC200 via a novel RNA-binding motif. J Biol Chem 280:33403-33410.
175. Zalfa F, Achsel T, Bagni C. 2006. mRNPs, polysomes or granules: FMRP in neuronal protein synthesis. Curr Opin Neurobiol 16:265-269.
176. Zalfa F, Eleuteri B, Dickson KS, Mercaldo V, De Rubeis S, di Penta A, Tabolacci E, Chiurazzi P, Neri G, Grant SG, Bagni C. 2007. A new function for the fragile X mental retardation protein in regulation of PSD-95 mRNA stability. Nat Neurosci 10:578-587.
177. Zhang Y, Oconnor JP, Siomi MC, Srinivasan S, Dutra A, Nussbaum RL, Dreyfuss G. 1995. The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO J 14:5358-5366.
178. Zhang YQ, Bailey AM, Matthies HJ, Renden RB, Smith MA, Speese SD, Rubin GM, Broadie K. 2001. Drosophila fragile X-related gene regulates the MAP1B homolog futsch to control synaptic structure and function. Cell 107:591-603.
179. Zhang M, Wang Q, Huang Y. 2007. Fragile X mental retardation protein FMRP and the RNA export factor NXF2 associate with and destabilize Nxf1 mRNA in neuronal cells. Proc Natl Acad Sci USA 104:10057-10062.
180. Zukin RS, Richter JD, Bagni C. 2009. Signals, synapses, and synthesis: How new proteins control plasticity. Front Neural Circuits 3:14.